Results 51 to 60 of about 125,474 (196)

Tamoxifen for the prevention of breast cancer results of Italian randomized tamoxifen prevention trial among women with hysterectomy

, 2007
Background Initial findings of the Italian Randomized Tamoxifen Prevention Trial found no reduction in risk of breast cancer with tamoxifen use, whereas the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial showed that ...
Viale G, Costa A, G. Gucciardo, P. Maisonneuve, Oliviero P, Conforti S, D'Aiuto G, M. R. del Turco, M. A. Pizzichetta, Rotmensz N, A. Costa, P. Boyle, Italian Tamoxifen Study Group, Sacchini V, del Turco MR, S. Conforti, G. Viale, Bonanni B, M. G. Muraca, Travaglini R, R. Travaglino, G. D’Aiuto, U. Veronesi, N. Rotmensz, Decensi A, Lovison F, PAGNI, Paola, Gucciardo G, Muraca MG, Italian Tamoxifen Study Group:, Veronesi U, B. Bonanni, Boyle P, A. Decensi, V. Sacchini, P. Oliviero, Pizzichetta MA, F. Lovison, Maisonneuve P   +38 more
core   +1 more source

The long noncoding RNA H19 promotes tamoxifen resistance in breast cancer via autophagy

Journal of Hematology & Oncology, 2019
Background Tamoxifen resistance remains a clinical challenge for hormone receptor-positive breast cancer. Recently, dysregulations in autophagy have been suggested as a potential mechanism for tamoxifen resistance.
Ji Wang, Shuduo Xie, Jingjing Yang, Hanchu Xiong, Yunlu Jia, Yulu Zhou, Yongxia Chen, Xiaogang Ying, Cong Chen, Chenyang Ye, Linbo Wang, Jichun Zhou   +11 more
doaj   +1 more source

First-in-human pharmacokinetics of tamoxifen and its metabolites in the milk of a lactating mother: a case study

ESMO Open, 2020
BackgroundBreast cancer represents the most frequent neoplasm diagnosed in women of childbearing age. When the tumour is oestrogen receptor-positive, tamoxifen is among the recommended endocrine treatments.
Fedro Alessandro Peccatori, Giovanni Codacci-Pisanelli, Gunnar Mellgren, Barbara Buonomo, Eleonora Baldassarre, Ernst Asbjorn Lien, Ersilia Bifulco, Steinar Hustad, Emil Zachariassen, Harriet Johansson, Thomas Helland   +10 more
doaj   +1 more source

A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer

npj Breast Cancer
Palbociclib combined with endocrine therapy is approved for treating patients with hormone-receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer; however, data on palbociclib combined with tamoxifen are ...
Emi Noguchi, Takashi Yamanaka, Hirofumi Mukai, Naohito Yamamoto, Chi-Feng Chung, Yen-Shen Lu, Dwan-Ying Chang, Joohyuk Sohn, Gun Min Kim, Kyung-Hun Lee, Soo-Chin Lee, Tsutomu Iwasa, Hiroji Iwata, Kenichi Watanabe, Kyung Hae Jung, Yuko Tanabe, Seok Yun Kang, Hiroyuki Yasojima, Kenjiro Aogi, Eriko Tokunaga, Sung Hoon Sim, Yoon Sim Yap, Koji Matsumoto, Ling-Ming Tseng, Yoshiko Umeyama, Kazuki Sudo, Yuki Kojima, Tomomi Hata, Aya Kuchiba, Taro Shibata, Kenichi Nakamura, Yasuhiro Fujiwara, Kenji Tamura, Kan Yonemori   +33 more
doaj   +1 more source

Tamoxifen-injected iMfn2^DA mice show impaired locomotion and DA neurodegeneration.

, 2021
Control and iMfn2DA mice were analyzed at 3, 6 and 9 weeks after tamoxifen or vehicle injection. (A) Spontaneous motor activity (horizontal activity, vertical activity and total distance) was measured in open field. ***p14. (B-C) Representative images of
Seungmin Lee (68256), Thomas Perlmann (11485872), Elena Sopova (11485866), Mara Mennuni (11485860), Viktor Jonsson (3467864), Katarína Tiklová (87618), Roberta Filograna (789459), Oleg Shupliakov (89781), Nils-Göran Larsson (106099), Camilla Koolmeister (11485869), Markus Ringnér (3876), Linda Gillberg (11485863), Lars Olson (157339)   +12 more
core   +1 more source

Developmental malformations resulting from high-dose maternal tamoxifen exposure in the mouse.

PLoS ONE, 2021
Tamoxifen is an estrogen receptor (ER) ligand with widespread use in clinical and basic research settings. Beyond its application in treating ER-positive cancer, tamoxifen has been co-opted into a powerful approach for temporal-specific genetic ...
Miranda R Sun, Austin C Steward, Emma A Sweet, Alexander A Martin, Robert J Lipinski   +4 more
doaj   +1 more source

Tamoxifen-inducible Cre-mediated Rpa1 deletion strategy during male meiosis.

, 2019
(A) Schematic diagram of various Rpa1 alleles: Rpa1tm1a, Rpa1fl (floxed allele), and Rpa1 knockout. Cre-mediated deletion of exon 8 (encoding residues 182–226) is expected to cause a frameshift in the resulting mutant transcript.
Mingxi Liu (129494), Lan Ye (140528), Qinghua Shi (169845), Baolu Shi (2328775), Mengcheng Luo (687507), Jiahao Sha (129501), Xiaoyan Huang (112885), Rui Guo (134395), P. Jeremy Wang (119396), Hao Yin (381910), Jiangyang Xue (4762836)   +10 more
core   +1 more source

Analysis of information received during treatment and adherence to tamoxifen in breast cancer patients [PDF]

, 2017
This study examines whether women with breast cancer, who are adherent and non-adherent to tamoxifen, differ in their perceptions of information received during treatment.
Priscila Mazzola, Aline Cruz, Rebeca Stahlschmidt, Nice Silva, Amanda Ferracini, Aline Rodrigues   +5 more
core   +1 more source

Comparative Effects of Tamoxifen and Anastrozole on Lipid Profile and Liver Enzymes in Patients with Breast Cancer [PDF]

Kirkuk Journal of Medical Sciences
Background: Breast cancer has emerged as one of the most common malignancies diagnosed among women worldwide. Hormone therapy with Tamoxifen or aromatase inhibitors is an essential part of the treatment for estrogen-receptor-positive breast cancer ...
Jangi Salai, Jwan Mohammed
doaj   +1 more source

The role of CtIP (RBBP8) in tamoxifen resistance and human breast cancer [PDF]

, 2007
textAcquired resistance to the antiestrogen tamoxifen constitutes a major clinical challenge in breast cancer therapy. However, the mechanisms involved are still poorly understood.
Wu, Minhao, 1976-
core